Wegovy 9 mg Tablets – Semaglutide Medical Information
Wegovy 9 mg tablets Overview
Wegovy 9 mg is an oral tablet formulation containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It represents the third strength in the oral Wegovy dose-escalation schedule for eligible adults receiving prescription weight-management treatment.
Semaglutide works by activating GLP-1 receptors involved in appetite regulation, food intake and glucose metabolism. Its effects on hunger and feelings of fullness contribute to its role in chronic weight-management treatment.
The 9 mg tablet follows the initial 1.5 mg and second-stage 4 mg strengths. It is an intermediate treatment stage before the 25 mg maintenance strength in the published oral dosing schedule.
Gradual dose escalation allows healthcare professionals to assess treatment tolerability and determine whether progression to the next strength is appropriate.
In Australia, Wegovy 9 mg tablets were registered by the Therapeutic Goods Administration (TGA) on 3 November 2026 under ARTG number 522758. Registration does not necessarily indicate immediate commercial availability.
Wegovy 9 mg tablets Product Information
| Product characteristic | Details |
|---|---|
| Brand name | Wegovy |
| Active ingredient | Semaglutide |
| Strength | 9 mg |
| Dosage form | Oral tablet |
| Administration | Oral |
| Frequency | Once daily |
| Drug class | GLP-1 receptor agonist |
| Treatment stage | Third dose-escalation stage |
| Manufacturer | Novo Nordisk |
| Australian sponsor | Novo Nordisk Pharmaceuticals Pty Ltd |
| Australian registration | ARTG 522758 |
| Medicine classification | Prescription medicine |
What Is Semaglutide?
Semaglutide is a medication that mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in appetite regulation and glucose metabolism.
It activates GLP-1 receptors that influence several physiological processes, including hunger signals, feelings of fullness, gastric emptying and glucose-dependent insulin secretion.
Semaglutide is used in certain prescription treatments for metabolic conditions and chronic weight management. Its effects on appetite and food intake are particularly relevant to its role in obesity treatment.
How Does Wegovy 9 mg tablets Work?
Wegovy 9 mg works through the activity of semaglutide on GLP-1 receptors.
After absorption, semaglutide influences appetite-related pathways and helps regulate food intake. Its effects may include:
- Appetite regulation: Influences the signals associated with hunger and food consumption.
- Increased satiety: Helps increase feelings of fullness after meals.
- Gastric emptying: Influences the rate at which food moves from the stomach into the small intestine.
- Glucose regulation: Supports glucose-dependent insulin secretion and contributes to blood glucose regulation.
These mechanisms explain how semaglutide can support weight-management treatment when combined with appropriate nutritional and physical activity interventions.
Individual responses vary, and treatment should be monitored by a qualified healthcare professional.
Why Is 9 mg the Third Strength?
The 9 mg tablet represents the third stage in the oral Wegovy dose-escalation schedule.
It follows the initial 1.5 mg strength and the subsequent 4 mg strength. This gradual progression is designed to introduce increasing amounts of semaglutide over time.
Dose escalation is important because gastrointestinal adverse reactions, including nausea, vomiting and diarrhoea, can occur during semaglutide treatment.
The 9 mg stage provides an intermediate step before the 25 mg maintenance strength.
The 9 mg tablet is not the standard maintenance strength in the published oral dosing schedule. Treatment progression should be determined by the prescribing healthcare professional.
Wegovy Oral Tablet Dosage Schedule
The published oral semaglutide dosing schedule involves four tablet strengths.
| Treatment period | Daily strength | Treatment stage |
|---|---|---|
| Days 1–30 | 1.5 mg | Initial stage |
| Days 31–60 | 4 mg | Second stage |
| Days 61–90 | 9 mg | Third stage |
| Day 91 onwards | 25 mg | Maintenance stage |
Each dose-escalation stage generally lasts at least 30 days.
If a patient does not tolerate a particular strength, the healthcare professional may consider delaying further dose escalation.
Patients should not independently increase their dosage, combine multiple tablet strengths or change their treatment schedule.
How to Take Oral Wegovy 9 mg Tablets
Oral semaglutide has specific administration requirements because food, beverages and other oral medicines can affect its absorption.
The published administration instructions include:
- Take the tablet in the morning after an overnight fast of at least eight hours.
- Swallow the tablet whole with plain water.
- Use no more than 120 mL of water.
- Do not crush, chew, split or dissolve the tablet.
- Wait at least 30 minutes before eating, drinking or taking other oral medicines.
Following these administration instructions is important for consistent medication absorption.
Patients should follow the current Australian-approved Product Information and instructions provided by their prescribing healthcare professional or pharmacist.
Possible Side Effects of Wegovy 9 mg tablets
Like other semaglutide-containing medicines, Wegovy may cause adverse reactions.
Gastrointestinal effects are among the commonly reported reactions, particularly during treatment initiation and dose escalation.
Potential side effects include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort
- Bloating
- Indigestion
- Reduced appetite
Some symptoms may improve as the body adjusts to treatment. However, persistent, severe or unusual symptoms should be discussed with a healthcare professional.
More serious potential risks include pancreatitis, gallbladder disease, dehydration-related kidney problems and serious allergic reactions.
Severe or persistent abdominal pain, particularly when accompanied by vomiting, requires urgent medical assessment.
Warnings and Precautions
Before starting or continuing semaglutide treatment, patients should discuss their medical history with their healthcare professional.
Important considerations include:
- Previous pancreatitis.
- Gallbladder disease or gallstones.
- Kidney problems.
- Diabetes and medicines that may cause hypoglycaemia.
- Severe gastrointestinal conditions.
- Pregnancy or plans for pregnancy.
- Breastfeeding.
- Previous allergic reactions to semaglutide or formulation ingredients.
Semaglutide should not be used for weight reduction during pregnancy. Patients planning pregnancy should discuss the appropriate discontinuation period with their healthcare professional.
The current Australian-approved Product Information should be consulted for complete contraindications, warnings and precautions.
Wegovy 9 mg tablets Drug Interactions
Semaglutide may influence the absorption of certain oral medicines because it can delay gastric emptying.
Patients should inform their healthcare professional about all medicines they use, including:
- Prescription medications.
- Non-prescription medicines.
- Diabetes treatments.
- Vitamins and supplements.
- Medicines requiring close therapeutic monitoring.
Additional monitoring may be necessary when semaglutide is used alongside certain diabetes medications or medicines with a narrow therapeutic index.
Patients should not combine Wegovy with other semaglutide-containing products or GLP-1 receptor agonists unless specifically directed by an appropriate healthcare professional.
Wegovy 9 mg vs Wegovy Injection
Oral Wegovy and injectable Wegovy contain the same active ingredient, semaglutide, but have different administration methods and dosing schedules.
| Characteristic | Oral Wegovy | Injectable Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Administration | Oral tablet | Subcutaneous injection |
| Frequency | Once daily | Once weekly |
| 9 mg strength | Third oral dose-escalation stage | Not an equivalent injection dose |
| Maintenance strength | 25 mg daily | Depends on the approved injectable regimen |
The numerical strengths of oral and injectable semaglutide are not directly interchangeable because their absorption characteristics differ.
Patients should not independently switch formulations or calculate equivalent doses.
Wegovy 9 mg tablets in Australia
Wegovy 9 mg tablets were registered in the Australian Register of Therapeutic Goods on 3 November 2026.
Australian registration information:
- Product: Wegovy semaglutide 9 mg tablet blister pack.
- ARTG number: 522758.
- Active ingredient: Semaglutide.
- Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd.
- Registration date: 3 November 2026.
- Medicine classification: Prescription medicine.
The TGA registration confirms the product’s inclusion in the Australian Register of Therapeutic Goods.
However, registration should not be confused with immediate commercial availability, pharmacy stock or Pharmaceutical Benefits Scheme (PBS) subsidy.
Australian patients and healthcare professionals should consult the TGA and the manufacturer for current supply information and approved product documentation.
Storage and Handling
Wegovy tablets should be stored according to the conditions specified in the approved product packaging and Consumer Medicine Information.
Keep medicines away from children and do not use tablets beyond their expiry date.
Consult the product documentation for specific storage temperatures, packaging requirements and handling instructions.
Frequently Asked Questions About Wegovy 9 mg
What is Wegovy 9 mg tablets used for?
Wegovy 9 mg is the third strength in the oral semaglutide dose-escalation schedule. It follows the 1.5 mg and 4 mg treatment stages before the 25 mg maintenance strength.
Is Wegovy 9 mg a daily tablet?
Yes. The oral formulation is designed for once-daily administration, following specific fasting and water requirements.
How long is Wegovy 9 mg tablets taken?
The standard dose-escalation schedule uses the 9 mg strength for at least 30 days. Treatment progression depends on individual tolerability and the prescribing healthcare professional’s assessment.
What comes after Wegovy 9 mg tablets?
The published oral dosing schedule progresses from 9 mg to the 25 mg maintenance strength.
Is Wegovy 9 mg tablets a maintenance dose?
No. The 9 mg tablet is an intermediate dose-escalation strength. The standard oral maintenance strength is 25 mg once daily.
Can Wegovy 9 mg tablets be taken with food?
The oral formulation should be taken after an overnight fast with plain water. Patients should wait at least 30 minutes before eating, drinking or taking other oral medicines.
Is Wegovy 9 mg the same as a 9 mg injection?
No. The 9 mg oral tablet is not equivalent to a 9 mg injectable dose. Oral and injectable semaglutide have different absorption characteristics and dosing schedules.
Is Wegovy 9 mg tablets registered in Australia?
Yes. The TGA registered the 9 mg oral tablet formulation on 3 November 2026 under ARTG number 522758.
Does Wegovy 9 mg tablets guarantee weight loss?
No. Individual responses to semaglutide vary. Treatment should be considered as part of a comprehensive weight-management programme under medical supervision.
Is Wegovy 9 mg tablets the same as Rybelsus?
No. Both products contain semaglutide, but they have different product indications, strengths and dosing schedules. They should not be treated as interchangeable.
Medical Disclaimer
This information is provided for general educational purposes only. It does not replace professional medical advice, diagnosis or treatment.
Wegovy is a prescription medicine. Patients should consult a qualified Australian healthcare professional before starting, changing or stopping any medication.
Medical information should be checked against the latest Australian-approved Product Information and Consumer Medicine Information before publication.
Important regulatory consideration: Prescription-only medicines have strict advertising restrictions in Australia under the Therapeutic Goods Act and TGA advertising requirements. Public-facing promotion of prescription-only Wegovy, including product-specific promotional descriptions, calls to purchase and testimonials, can be problematic. Keep these pages educational and non-promotional, and obtain Australian regulatory review before publishing commercial product listings.
Useful references:
Reviews
There are no reviews yet.